ECO 2026 12 - 15 May 2026

Renal or Hepatic Impairment Does Not Affect the Pharmacokinetics, Safety or Tolerability of Subcutaneous Cagrilintide

Sorry! It looks like the page you are trying to access contains materials that are still under embargo. Please come back and check again later.
Keywords
Obesity
Congress poster
GLP-1 RA
Cagrilintide
Pre-clinical